• SearchField_GetLegal

Neurontin

The FDA approved Neurontin in 1994 for treatment of partial seizures usually associated with epilepsy. It was later approved for pain management associated with postherpetic neuralgia as a result of shingles.

Pfizer Markets Neurontin for Off-Label Use

Shortly after Neurontin appeared on the market, the manufacturer, Pfizer, began intensive marketing of the drug for off-label purposes not approved by the FDA, including bipolar disorder, attention deficit disorder, migraines and drug and alcohol withdrawal.

Pfizer also marketed the drug for use as a first-line monotherapy treatment for epilepsy, which the FDA had previously rejected. Pfizer continued to implement marketing techniques that illegally promoted Neurontin, influencing off-label uses based on unproven claims. These actions may have caused both patients and doctors to be unable to weigh both the benefits and risks of using the drug.

To learn more about legal claims relating to Neurontin, consult an attorney who practices in the area of drugs and medical devices.

Connect with Top-rated Attorneys Near You

    Latest Article

      GETLEGAL®ATTORNEY DIRECTORY

      Find Leading Attorneys in Your Area

          NEED PROFESSIONAL HELP?

          Talk to an Attorney

          How It Works

          • Briefly tell us about your case
          • Provide your contact information
          • Choose attorneys to contact you
          • SearchField_GetLegal

          ABOUT GETLEGAL

          Our mission at GetLegal is to develop a family of sites that constitute the most useful, informative, reliable and exciting collection of legal resources on the web. We are constantly working to expand and improve many resources we offer to legal professionals and the public.

          Contact Us : 817-359-7077

          RECENT TWEETS

          NEWSLETTER SIGN-UP

          By submitting information to this site, you give permission to GetLegal, or a partner of GetLegal, to contact you by email.

          Advertise With Us

          © 2008-2021 LawConnect, Inc. All rights reserved. Sitemap | Copyright/DMCA Policy | Privacy Policy | Terms of Use | Disclosures/Disclaimers